Nathan D Seligson
Overview
Explore the profile of Nathan D Seligson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Seligson J, Patron A, Berger M, Harvey R, Seligson N
Ann Pharmacother
. 2020 Oct;
55(7):921-931.
PMID: 33070624
Objective: To review the pharmacology, efficacy, and safety of sacituzumab govitecan (-hziy; IMMU-132, Trodelvy) for patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies...
22.
Seligson N, Warner J, Dalton W, Martin D, Miller R, Patt D, et al.
J Am Med Inform Assoc
. 2020 Sep;
27(11):1808-1812.
PMID: 32885823
Defining patient-to-patient similarity is essential for the development of precision medicine in clinical care and research. Conceptually, the identification of similar patient cohorts appears straightforward; however, universally accepted definitions remain...
23.
Faheem M, Seligson N, Ahmad S, Rasool R, Gandhi S, Bhagat M, et al.
Cell Death Discov
. 2020 Jun;
6:51.
PMID: 32566256
Drug induced resistance is a widespread problem in the clinical management of cancer. Cancer cells, when exposed to cytotoxic drugs, can reprogram their cellular machinery and resist cell death. Evasion...
24.
Seligson N, Knepper T, Ragg S, Walko C
Clin Pharmacol Ther
. 2020 Jun;
109(2):334-342.
PMID: 32535906
Targeted therapies have reshaped the landscape of the development of cancer therapeutics. Recent biomarker-driven, tissue-agnostic clinical trials represent a significant paradigm shift in precision cancer medicine. Despite their growth in...
25.
Chakraborty S, Bashir Mir K, Seligson N, Nayak D, Kumar R, Goswami A
Cancer Metastasis Rev
. 2020 Feb;
39(2):553-566.
PMID: 32020420
Apoptosis is a tightly controlled, coordinated cellular event responsible for inducing programmed cell death to rid the body of defective or unfit cells. Inhibition of apoptosis is, therefore, an essential...
26.
Seligson N, Stets C, Demoret B, Awasthi A, Grosenbacher N, Shakya R, et al.
Oncotarget
. 2019 Oct;
10(55):5671-5679.
PMID: 31620242
Dedifferentiated liposarcoma (DDLPS) is a highly morbid mesenchymal tumor characterized and driven by genomic amplification of the gene. Direct inhibition of MDM2 has shown promise pre-clinically, but has yet to...
27.
Seligson N, Awasthi A, Millis S, Turpin B, Meyer C, GrandMaison A, et al.
JAMA Netw Open
. 2019 Oct;
2(10):e1912416.
PMID: 31577358
Importance: Epithelioid hemangioendothelioma (EHE) is a rare, malignant vascular sarcoma characterized in most cases by a WWTR1-CAMTA1 fusion. The clinical course of EHE exhibits a dual nature. The condition is...
28.
Bill K, Seligson N, Hays J, Awasthi A, Demoret B, Stets C, et al.
Oncologist
. 2019 Apr;
24(7):989-996.
PMID: 31019022
Background: Dedifferentiated liposarcomas (DDLPS) are mesenchymal tumors associated with universally poor response to treatment. Genomic amplification of murine double minute 2 () is used as a diagnostic biomarker; however, no...
29.
Seligson N, Kautto E, Passen E, Stets C, Toland A, Millis S, et al.
Oncologist
. 2018 Dec;
24(7):973-979.
PMID: 30541756
Background: Soft-tissue sarcomas (STS) describe a heterogeneous group of mesenchymal tumors with limited treatment options. Targeted therapies exist for gene alterations, but their prevalence and role have not been fully...
30.
Seligson N, Hobbs A, Leonard J, Mills E, Evans A, Goorha S
Ann Pharmacother
. 2017 Dec;
52(5):439-445.
PMID: 29241342
Background: Treatment for acute myeloid leukemia (AML) has remained relatively unchanged over the past few decades. Although recent drug approvals have provided an increase in the number of treatment options...